XNASELAB
Market cap7mUSD
Dec 27, Last price
2.44USD
1D
1.24%
1Q
2,543.55%
IPO
-29.68%
Name
ELEVAI Labs Inc
Chart & Performance
Profile
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
Income | ||||
Revenues | 1,713 123.50% | 766 92,557.44% | 827 | |
Cost of revenue | 5,032 | 2,282 | 761 | |
Unusual Expense (Income) | ||||
NOPBT | (3,320) | (1,516) | (760) | |
NOPBT Margin | ||||
Operating Taxes | (2) | 3 | ||
Tax Rate | ||||
NOPAT | (3,320) | (1,516) | (760) | |
Net income | (4,302) 138.94% | (1,800) 129.41% | (785) 252.04% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 7,464 | 2,178 | 1,091 | |
BB yield | -37.99% | |||
Debt | ||||
Debt current | 145 | 111 | ||
Long-term debt | 276 | 345 | ||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (2,906) | (710) | (412) | |
Cash flow | ||||
Cash from operating activities | (4,557) | (1,586) | (661) | |
CAPEX | (11) | (36) | (32) | |
Cash from investing activities | (11) | (32) | (32) | |
Cash from financing activities | 6,739 | 2,362 | 1,091 | |
FCF | (3,689) | (1,807) | (802) | |
Balance | ||||
Cash | 3,327 | 1,155 | 412 | |
Long term investments | 11 | |||
Excess cash | 3,241 | 1,127 | 412 | |
Stockholders' equity | (7,022) | (2,721) | (921) | |
Invested Capital | 11,060 | 4,135 | 1,371 | |
ROIC | ||||
ROCE | ||||
EV | ||||
Common stock shares outstanding | 10,746 | 9,529 | 17,330 | |
Price | 1.83 | |||
Market cap | 19,646 | |||
EV | 16,740 | |||
EBITDA | (3,308) | (1,509) | (757) | |
EV/EBITDA | ||||
Interest | 20 | 3 | ||
Interest/NOPBT |